No Handouts for Drug Advertisements Act
- Bill Number
- S. 1785
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Taxation
- Status
- Introduced
- Latest Action
- 2025-05-15: Read twice and referred to the Committee on Finance.
- Last Updated
- 2025-12-05T21:48:17Z
AI-Generated Summary
Purpose
The "No Handouts for Drug Advertisements Act" (S. 1785) aims to reduce the financial incentives for pharmaceutical companies to advertise prescription drugs directly to consumers by eliminating tax deductions for such advertising expenses. This targets what sponsors view as excessive marketing of medications, potentially curbing industry spending on promotions.
Key Provisions
- New Tax Rule (Section 280I of the Internal Revenue Code): No tax deduction is allowed for expenses related to direct-to-consumer (DTC) advertising of "covered drugs" in any taxable year.
- Definition of DTC Advertising:
- Includes any ad disseminated by or for a covered entity that promotes a covered drug and is mainly aimed at the general public.
- Covers methods like radio, TV, phone systems, direct mail, billboards, internet, social media, apps, and digital platforms.
- Excludes ads in journals or periodicals (e.g., professional medical publications).
- Covered Entities:
- Sponsors of prescription drug products (as defined under the Federal Food, Drug, and Cosmetic Act, meaning companies that develop or market FDA-approved drugs).
- Owners of outsourcing facilities (compounding pharmacies that produce drugs in large batches under FDA oversight, as defined in sections 503A or 503B of the Act).
- Covered Drugs:
- Prescription drug products requiring a doctor's order.
- Drugs compounded (custom-mixed by pharmacists) under sections 503A (for individual patients) or 503B (for broader use) of the Federal Food, Drug, and Cosmetic Act.
- Effective Date: Applies to advertising expenses paid or incurred after the bill's enactment, for taxable years ending after that date.
Significant Changes to Existing Law
- Under current U.S. tax law (Internal Revenue Code), businesses can generally deduct ordinary advertising and promotional expenses as business costs to lower taxable income.
- This bill adds a specific disallowance (Section 280I) to Part IX of the Code, making DTC ads for covered drugs non-deductible—effectively increasing the after-tax cost of such advertising by the company's tax rate (e.g., up to 21% for corporations).
- No changes to deductions for other business ads or non-DTC promotions (e.g., ads to doctors).
Potential Impacts
- On Government Agencies: The Internal Revenue Service (IRS) and Treasury Department would enforce the new rule, potentially increasing federal tax revenue from pharmaceutical companies by disallowing deductions (estimated impacts not specified in the bill but could be significant given U.S. drug ad spending exceeds $6 billion annually).
- On Citizens: May lead to fewer DTC drug ads on TV, online, or billboards, reducing consumer exposure to marketing that could influence prescribing habits or healthcare decisions; however, it does not ban ads outright.
- On Pharmaceutical Industry: Raises costs for DTC campaigns, possibly shifting spending to non-deductible or alternative promotions, or reducing overall advertising budgets.
- On International Relations: Minimal direct impact, as the bill focuses on U.S. tax policy for domestic and U.S.-based entities; foreign pharma firms operating in the U.S. could be affected if they qualify as covered entities.
Main Stakeholders Affected
- Pharmaceutical Companies and Sponsors: Primary targets, as they lose tax benefits for DTC ads, potentially altering marketing strategies.
- Compounding Pharmacies and Outsourcing Facilities: Owners may face limits on promoting custom drugs.
- Advertising Agencies and Media Outlets: Could see reduced demand for DTC drug ad placements (e.g., TV networks, digital platforms).
- Taxpayers and Consumers: Indirectly benefit from higher corporate taxes and possibly less aggressive drug marketing; healthcare providers may see changes in patient requests for advertised drugs.
- Government (IRS and Congress): Gains enforcement role and revenue; reflects bipartisan effort to address pharma practices.
Notable Legal, Constitutional, or Political Implications
- Legal: Amends the tax code narrowly to target DTC ads without prohibiting them, but could invite lawsuits over IRS enforcement or definitions (e.g., what counts as "primarily targeted to the general public"). Relies on cross-references to the Federal Food, Drug, and Cosmetic Act for drug definitions.
- Constitutional: May raise First Amendment concerns, as DTC drug ads are protected commercial speech (upheld in cases like Sorrell v. IMS Health); critics could argue it indirectly burdens speech, though tax deductions are government incentives, not mandates.
- Political: Introduced bipartisanship (by Sen. Hawley, R-MO, and Sen. Shaheen, D-NH) signals cross-aisle concern over pharma influence; referred to the Senate Finance Committee, indicating focus on fiscal policy rather than direct regulation. Could influence broader debates on drug pricing and advertising in the U.S., where DTC ads are unique globally.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (2)
Sen. Shaheen, Jeanne [D-NH], Sen. Slotkin, Elissa [D-MI]
Recent Actions
- 2025-05-15: Read twice and referred to the Committee on Finance.
- 2025-05-15: Introduced in Senate
Bill Versions
- No Handouts for Drug Advertisements Act — issued 2025-05-15 — PDF (4 pages)